Tumor necrosis factor and its targets in the inflammatory cytokine pathway are identified as putative transcriptomic biomarkers for escitalopram response

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1105-1114

  Powell, Timothy R ^a   Schalkwyk, Leonard C ^a   Heffernan, Andrew L ^a   Breen, Gerome ^a   Lawrence, Timothy ^a   Price, Tom ^a   Farmer, Anne E ^a   Aitchison, Katherine J ^a,b   Craig, Ian W ^a   Danese, Andrea ^a   Lewis, Cathryn ^a   McGuffin, Peter ^a   Uher, Rudolf ^a,c   Tansey, Katherine E ^a   D'Souza, Ursula M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Biomarker; Escitalopram; Pharmacogenetic; SSRI; TNF

Indexed keywords

ESCITALOPRAM; INTERLEUKIN 11; INTERLEUKIN 6; NORTRIPTYLINE; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC DIFFERENCE; GENETIC TRANSCRIPTION; GENOME ANALYSIS; GENOTYPE; HUMAN; MAJOR DEPRESSION; MALE; MENTAL PATIENT; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; PSYCHOPHARMACOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

BIOMARKER; ESCITALOPRAM; PHARMACOGENETIC; SSRI; TNF;

ADULT; AGED; BIOLOGICAL MARKERS; CITALOPRAM; CYTOKINES; DEPRESSIVE DISORDER; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN UPTAKE INHIBITORS; TRANSCRIPTOME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84884210609     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.09.009     Document Type: Article

References (31)

1. Abdel-Salam O.M.E., Nofal S.M., El-Shenawy S.M. Evaluation of the anti-inflammatory and anti-nociceptive effects of different antidepressants in the rat. Pharmacol. Res. 2003, 48:157-165.
2. Andersen C.L., Jensen J.L., Orntoft T.F. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suitable for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64:5245.
3. Cassel S., Carouge D., Gensburger C., Anglard P., Burgun C., Dietrich J-B., Aunis D., Zwiller J. Fluoxetine and cocaine induce the epigenetic factors MeCP2 and MBD1 in adult rat brain. Mol. Pharmacol. 2006, 70:487-492.
4. Cattaneo, A., Gennarelli, M., Uher, R., Breen, G., Farmer, A., Aitchison, K.J., Craig, I.W., Anacker, C., Zunsztain, P.A., McGuffin, P., Pariante, C.M., 2012. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology, advance online publication, 19 September 2012, http://dx.doi.org/10.1038/npp.2012.191.
5. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., LanctÔt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
6. Eller T., Vasar V., Shlik J., Maronc E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog. Neuro-psychopharmacol. 2008, 32:445-450.
7. Iosif R.E., Ekdahl C.T., Ahlenius H., Pronk C.J.H., Bonde S., Kokaia Z., Jacobsen S., Lindvall O. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J. Neurosci. 2003, 26:9703-9712.
8. Kahl K.G., Kruse N., Faller H., Weiss H., Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002, 27:671-681.
9. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
10. Maas W.D., Westendorp R.G.J., Willems J.M., de Craen A.J.M., van der Mast R.C. TNF-[alpha] antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. J. Clin. Psychopharmacol. 2010, 30:343-345.
11. Maes M., Bosmans E., Jongh R.D., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
12. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumour necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001, 11:203-208.
13. Miller, A.A. Study of Infliximab for Treatment Resistant Major Depression (last accessed 2012). http://clinicaltrials.gov/ct2/show/study/NCT00463580?cond=%22Depression%22&rank=1.
14. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2008, 65:732-741.
15. Monje M.L., Toda H., Palmer T. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003, 302:1760-1765.
16. Montgomery S.A., Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134:382-389.
17. Mossner R., Heils A., Stober G., Okladnova O., Daniels S., Lesch K.P. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem. Int. 1998, 33:251-254.
18. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M., Bender D., Maller J., Sklar P., de Bakker P.I.W., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 2007, 81:559-575.
19. Roumestan C., Michel A., Bichon F., Portet K., Detoc M., Henriquet C., Jaffuels D., Mathieu M. Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res. 2007, 8:35.
20. Rudge J.S., Eaton M.J., Mather P., Lindsay R.M., Whittemore S.R. CNTF induces raphe neuronal precursors to switch from a serotonergic to a cholinergic phenotype in vitro. Mol. Cell. Neurosci. 1996, 7:204-221.
21. Smith R.S. The macrophage theory of depression. Med. Hypotheses 1991, 35:298-306.
22. Sugden K., Pariante C.M., McGuffin P., Aitchison K.J., D'Souza U.M. Housekeeping gene expression is affected by antidepressant treatment in a mouse fibroblast cell line. J. Psychopharmacol. 2010, 24:1253-1259.
23. Thome J., Sakai N., Shin K-H., Steffen C., Zhang Y-J., Impey S., Storm D., Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 2000, 20:4030-4036.
24. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology 2003, 170:429-433.
25. Uher R., Farmer A., Maier W., Rietschel M., Hauser J., Marusic A. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol. Med. 2008, 38:289-300.
26. Uher R., Huezo-Diaz P., Perroud N., Smith R., Rietschel M., More O., et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J. 2009, 9:225-233.
27. Uher R., Perroud N., Ng M.Y.M., Hauser J., Henigsberg N., Maier W., et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 2010, 167:555-564.
28. Vandesompele J., Preter K.D., Pattyn F., Poppe B., Roy N.V., Paepe A.D., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. (RESEARCH0034).
29. Wing J.K., Sartorious N., Ustun T.B. Diagnosis and Clinical Measurement in Psychiatry: A Reference Manual for SCAN 1998, University Press, Cambridge.
30. Yang K., Xie G., Zhang Z., Wang C., Li W., Zhou W., Tang Y. Levels of serum interleukin (IL)-6, IL-1β, tumour necrosis factor-α and leptin and their correlation in depression. Aust. N. Y. J. Psychiatry 2007, 41:266-273.
31. Zhu C., Blakeky R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.